论文部分内容阅读
Objective: To observe the therapeutic effect of Bevacizumab (BEV) combined chemotherapy to treat persistent and/or recurrent uterine sarcomas.Method: From May 2006 to May 2014 clinical data from 4 persistent and/or recurrent uterine sarcoma patients who accepted BEV combined chemotherapy in our hospital was retrospectively analyzed.